148.00
148.00
Inclusive of all taxes
You Save: 0. Discount 0%
Product is not available
GLIPVAS MET TAB is a powerful fixed-dose combination of Vildagliptin and Metformin Hydrochloride, designed for effective control of blood glucose levels in patients with Type 2 Diabetes Mellitus. Manufactured by BluepillExpress, a globally accredited third-party pharmaceutical company, this combination tablet synergistically enhances insulin activity, reduces hepatic glucose output, and improves glycemic control. Available in various strengths, GLIPVAS MET TAB is globally exported and conforms to the highest standards of quality and regulatory compliance.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
GLIPVAS MET TAB is an advanced oral antidiabetic formulation that combines the therapeutic effects of Vildagliptin (50 mg) and Metformin Hydrochloride in different dosages (commonly 500 mg, 850 mg, or 1000 mg), offering a synergistic approach to managing Type 2 Diabetes Mellitus (T2DM). This dual-ingredient tablet not only reduces fasting and postprandial glucose levels but also improves beta-cell function and insulin sensitivity.
Manufactured by BluepillExpress, a certified and quality-driven third-party manufacturer, GLIPVAS MET TAB meets international pharmaceutical regulations and is available for export worldwide with complete documentation support. It is developed using high-grade APIs, precision manufacturing processes, and rigorous quality control systems in WHO-GMP-approved facilities.
Mechanism of Action
Vildagliptin is a DPP-4 inhibitor that increases the levels of incretin hormones (GLP-1 and GIP), thereby enhancing insulin secretion and suppressing glucagon production in a glucose-dependent manner.
Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues.
Together, these actions provide a complementary and more comprehensive glycemic control strategy for Type 2 diabetic patients.
Indications
Type 2 Diabetes Mellitus in adults
Especially effective in patients who are inadequately controlled by monotherapy
Suitable as an initial therapy in newly diagnosed patients with high baseline glucose levels
Dosage and Administration
Usual Dosage:
Vildagliptin 50 mg + Metformin 500 mg/850 mg/1000 mg
Administration:
Oral, with meals to minimize gastrointestinal side effects
Twice daily dosing is typical for optimal blood sugar control
Adjustments:
Based on renal function, tolerance, and physician recommendation
Note:
Not recommended for patients with severe renal impairment or acute metabolic complications
Pharmacokinetics
Vildagliptin: Rapid absorption; peak plasma in 1.5 hours; half-life ~3 hours
Metformin: Not metabolized; excreted unchanged via kidneys; half-life ~6 hours
No significant pharmacokinetic interactions between the two drugs